Grab Holdings Ltd. vs State Street SPDR S&P Biotech ETF — how do they compare? Grab Holdings Ltd. trades at $3.63 (market cap $15.26B), while State Street SPDR S&P Biotech ETF trades at $159.32. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | XBI | |
|---|---|---|
Market Cap | $15.26B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $6.45 | $164.28 |
52-Week Low | $3.27 | $86.92 |
Enterprise Value | $10.99B | — |
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.625, down 1.23% on the day, showing strong fundamental momentum with three consecutive quarterly earnings beats and a significant turnaround to profitability. The company reported Q2 2026 EPS of $0.06 versus $0.05 expected, with revenue growth accelerating to $3.37 billion in 2025. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions near-term.
GRAB presents a compelling growth story with improving profitability and strong analyst support (91.67% buy ratings). The company's raised 2026 guidance and expanding super app ecosystem signal continued momentum. Key risks include volatile cash flow patterns, competitive pressures in Southeast Asia, and recent insider selling activity that warrants monitoring.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Trailing returns across standard periods
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →